Natixis Advisors LLC reduced its position in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 69.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 296,048 shares of the company’s stock after selling 659,258 shares during the period. Natixis Advisors LLC’s holdings in Kenvue were worth $5,107,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in KVUE. Norges Bank acquired a new stake in shares of Kenvue during the 4th quarter valued at approximately $756,862,000. Van ECK Associates Corp raised its position in shares of Kenvue by 101.3% during the 3rd quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock valued at $298,008,000 after acquiring an additional 9,240,434 shares in the last quarter. American Century Companies Inc. raised its position in shares of Kenvue by 22.4% during the 3rd quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock valued at $601,267,000 after acquiring an additional 6,781,640 shares in the last quarter. Bessemer Group Inc. raised its position in shares of Kenvue by 156.2% during the 4th quarter. Bessemer Group Inc. now owns 8,491,343 shares of the company’s stock valued at $146,475,000 after acquiring an additional 5,177,404 shares in the last quarter. Finally, Mondrian Investment Partners LTD acquired a new stake in shares of Kenvue during the 3rd quarter valued at approximately $79,269,000. 97.64% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In related news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 1.59% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
Kenvue Trading Down 0.9%
NYSE:KVUE opened at $17.56 on Tuesday. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $22.87. The stock has a market cap of $33.71 billion, a price-to-earnings ratio of 20.65, a PEG ratio of 1.34 and a beta of 0.54. The business has a fifty day moving average of $17.37 and a 200-day moving average of $17.49. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98.
Kenvue (NYSE:KVUE – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. During the same quarter in the prior year, the business posted $0.24 earnings per share. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. Equities analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current year.
Kenvue Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were paid a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.7%. Kenvue’s dividend payout ratio is presently 97.65%.
About Kenvue
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Featured Articles
- Five stocks we like better than Kenvue
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
